Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy
combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5
after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients
with multiple myeloma or lymphoma.